Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Operations (2016 - 2025)

Protalix BioTherapeutics has reported Cash from Operations over the past 16 years, most recently at 2030000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 2030000.0 for Q4 2025, down 49.14% from a year ago — trailing twelve months through Dec 2025 was 11993000.0 (down 238.26% YoY), and the annual figure for FY2025 was 11993000.0, down 238.26%.
  • Cash from Operations for Q4 2025 was 2030000.0 at Protalix BioTherapeutics, up from 3732000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for PLX hit a ceiling of 6516000.0 in Q2 2021 and a floor of 9834000.0 in Q1 2021.
  • Median Cash from Operations over the past 5 years was 3304000.0 (2023), compared with a mean of 1996100.0.
  • Biggest five-year swings in Cash from Operations: tumbled 389.57% in 2022 and later soared 239.69% in 2024.
  • Protalix BioTherapeutics' Cash from Operations stood at 5087000.0 in 2021, then skyrocketed by 48.67% to 2611000.0 in 2022, then skyrocketed by 237.69% to 3595000.0 in 2023, then increased by 11.02% to 3991000.0 in 2024, then crashed by 49.14% to 2030000.0 in 2025.
  • The last three reported values for Cash from Operations were 2030000.0 (Q4 2025), 3732000.0 (Q3 2025), and 5233000.0 (Q2 2025) per Business Quant data.